Skip to content

The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation

The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02372526
Enrollment
18
Registered
2015-02-26
Start date
2015-01-31
Completion date
2017-06-30
Last updated
2017-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery (Gastric Bypass), Overweight

Keywords

Glucagon-like Peptide-1, Glucose-dependent insulinotropic peptide, Glucagon, Peptide YY 3-36, Ghrelin, Body Weight, Obesity, Overnutrition, Overweight, Gastrointestinal Agents, GLP-1 secretagogue

Brief summary

The purpose of this study is to determine the type of macronutrient (carbohydrate, lipid or protein) that most potently stimulates the endogen secretion of different gut hormones (primary outcome = Glucagon-Like peptide-1) in gastric bypass operated patients. The study also includes a comparison of the secretion of gut hormones after oral intake of lipid with or without a pancreatic lipase inhibitor.

Interventions

OTHERMealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes
OTHERMealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes
OTHERMealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes
OTHERMealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes

Sponsors

University of Copenhagen
CollaboratorOTHER
Kirstine Nyvold Bojsen-Moeller
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

RYGB Patients: Inclusion Criteria: * Underwent RYGB surgery more than 18 months earlier, weight stabile (+/- 5 kg during 1 month)

Exclusion criteria

* Inadequate thyroid substitution, undergoing treatment with drugs known to interact with Orlistat (such as cyclosporine, anticoagulating agents, amiodarone, amlodipine and epileptics), where pausing the treatment with these is not an option. Type 1 or 2 diabetes mellitus now or prior to RYGB operation. Serious heart or respiratory illness. Haemoglobin levels below 6,5 mM. Healthy control subjects: Inclusion Criteria: * Have not underwent bariatric surgery.

Design outcomes

Primary

MeasureTime frameDescription
Within group difference in Glucagon-like Peptide 1 secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240I.e. Comparison of GLP-1 secretion (iAUC) as a result of intake of different macronutrients between a) gastric bypass patients only b) healthy volunteers only.

Secondary

MeasureTime frameDescription
Within group difference in Glucagon secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Within group difference in Glucose-dependent insulinotropic peptide secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Within group difference in Cholecystokinin secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Within group difference in Peptide YY 3-36 secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Within group difference in Ghrelin secretion (evaluated by iAUC).0, 30, 45, 60, 120, 180, 240
Within group difference in Changes in bile acids.0, 30, 45, 60, 120, 180, 240
Within group difference in Changes in glycerol, triacylglycerol and free fatty acids.0, 30, 45, 60, 120, 180, 240
Within group difference in Insulin secretion (evaluated by iAUC).2xBasline, 0, 10, 15, 20, 30, 40, 45, 60, 90, 120, 180, 240
Within group difference in Plasma glucose concentration.2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240
Within group difference in Visual Analog Scale.0, 30, 60, 90, 120, 180, 240Hunger, satiety, abdominal pain and nausea measured by standard 10 cm Visual Analog Scale
Within group difference in Ad libitum food intake (grams).240
Within group difference in Heart rate (bpm).2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240
Within group difference in Blood pressure (mmhg).0, 15, 30, 45, 60, 90, 120, 180, 240

Other

MeasureTime frameDescription
Between groups difference in Glucagon-like Peptide 1 secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240I.e. Comparison of GLP-1 secretion (iAUC) as a result of intake of different macronutrients between Gastric bypass operated patients and Healthy volunteers.
Between groups difference in Glucagon secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Between groups difference in Glucose-dependent insulinotropic peptide secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Between groups difference in Cholecystokinin secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Between groups difference in Peptide YY 3-36 secretion (evaluated by iAUC).Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240
Between groups difference in Ghrelin secretion (evaluated by iAUC).0, 30, 45, 60, 120, 180, 240
Between groups difference in Changes in bile acids.0, 30, 45, 60, 120, 180, 240
Between groups difference in Changes in glycerol, triacylglycerol and free fatty acids.0, 30, 45, 60, 120, 180, 240
Between groups difference in Insulin secretion (evaluated by iAUC).2xBasline, 0, 10, 15, 20, 30, 40, 45, 60, 90, 120, 180, 240
Between groups difference in Plasma glucose concentration.2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240
Between groups difference in Visual Analog Scale.0, 30, 60, 90, 120, 180, 240Hunger, satiety, abdominal pain and nausea measured by standard 10 cm Visual Analog Scale
Between groups difference in Ad libitum food intake (grams).240
Between groups difference in Heart rate (bpm).2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240
Between groups difference in Blood pressure (mmhg).0, 15, 30, 45, 60, 90, 120, 180, 240

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026